Want to see NUWE full AI Analyst Report?
NUWE Stock Chart & Stats
$2.05
-$0.15(-6.82%)
At close: 4:00 PM EDT
$2.05
-$0.15(-6.82%)
Day’s Range― - ―
52-Week Range$1.05 - $187.60
Previous CloseN/A
Volume154.60K
Average Volume (3M)289.18K
Market Cap
$4.23M
Enterprise Value-$3.16
Total Cash (Recent Filing)$3.92M
Total Debt (Recent Filing)$200.00K
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-132.69
Shares Outstanding3,647,264
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)4.58
Price to Sales (P/S)1.45
P/FCF Ratio-1.10
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-80.15
Revenue Forecast (FY)$9.87M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross-margin ImprovementThe combination of higher revenue and a 70.1% gross margin indicates improving product economics and commercial traction. If sustained, stronger pricing, mix and manufacturing efficiency could support eventual operating leverage as Aquadex utilization expands.
Pediatric Market AdoptionBroad pediatric adoption provides a focused growth avenue and supports clinical validation for Aquadex therapy. Penetration of major children's hospitals may strengthen reference accounts, expand the installed base and increase recurring circuit demand over time.
Expansion Of Cardiorenal Technology PlatformAdding kidney-function monitoring and protected pediatric safety technology broadens Nuwellis's clinical proposition beyond fluid removal alone. A more integrated cardiorenal platform could improve differentiation, support future products and create additional adoption opportunities.
Bears Say
Persistent Losses And Cash BurnDeep, recurring cash consumption means Nuwellis is not yet funding operations internally. Continued losses and negative free cash flow can restrict investment capacity, increase dependence on financing and delay the point at which revenue growth translates into durable financial strength.
Negative Equity And Financing DependenceNegative equity signals balance-sheet stress and limited financial flexibility despite low debt. Reliance on equity financings to support operations raises dilution risk and leaves the company exposed to the availability and terms of future capital.
Small Commercial Scale And Execution RiskRevenue remains modest relative to the cost base, so the business needs substantial growth or cost reduction to reach operating breakeven. The delayed 2027 product timeline also means anticipated acquisition benefits depend on several quarters of successful execution.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $1.05 and its highest was $187.60 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $4.23M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Aug 13, 2026. The company reported -$26.64 earnings per share for the quarter, missing the consensus estimate of -$23.8 by -$2.84.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Overvalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nuwellis have?
Nuwellis has 3,647,264 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of -$26.64 in its last earnings report, missing expectations of -$23.8. Following the earnings report the stock price went down -7.801%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
NUWE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple positive operational and strategic developments (notably 26% revenue growth, a 70.1% gross margin, pediatric adoption, the RendiaTech acquisition, a new patent, leadership and board strengthening, and a ~$5M capital infusion). However, notable challenges remain: a ~$4.3M net loss, operating expenses up ~46%, modest cash on hand (~$2.2M), and a multi-quarter timeline to commercialize RendiaTech's target product. On balance, the highlights indicate meaningful early execution progress and strategic positioning, but the company must deliver on its burn reduction and commercialization milestones to sustain momentum.View all NUWE earnings summariesTechnical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
<0.01% Insiders
0.37% Mutual Funds
0.45% Other Institutional Investors
99.18% Public Companies and
Individual Investors